Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance‐associated substitutions in naïve patients from Argentina
AP Martínez, G García, E Ridruejo… - Journal of medical …, 2019 - Wiley Online Library
Direct acting antiviral (DAA) therapy against hepatitis C virus (HCV) increases sustained
virologic response rates. Nevertheless, drug resistance has occasionally been associated …
virologic response rates. Nevertheless, drug resistance has occasionally been associated …
[HTML][HTML] Pretreatment hepatitis C virus NS5A/NS5B resistance-associated substitutions in genotype 1 Uruguayan infected patients
F Aldunate, N Echeverría, D Chiodi, P López… - Disease …, 2018 - hindawi.com
Hepatitis C Virus (HCV) infection treatment has dramatically changed with the advent of
direct-acting antiviral agents (DAAs). However, the efficacy of DAAs can be attenuated by …
direct-acting antiviral agents (DAAs). However, the efficacy of DAAs can be attenuated by …
Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies
M Grandal, B Pernas, A Tabernilla… - Journal of Medical …, 2018 - Wiley Online Library
The presence of resistance‐associated substitutions (RASs) at NS5A region might
compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A …
compromise the efficacy of Direct Acting Antiviral agents (DAAs). HCV resistance at NS5A …
Characterization of NS5A and NS5B Resistance-Associated Substitutions from Genotype 1 Hepatitis C Virus Infected Patients in a Portuguese Cohort
R Brandão, R Marcelino, F Gonçalves, I Diogo… - Viruses, 2018 - mdpi.com
This study is focused on the prevalent NS5 coding region resistance-associated
substitutions (RASs) in DAA-naive genotype (GT) 1 HCV-infected patients and their potential …
substitutions (RASs) in DAA-naive genotype (GT) 1 HCV-infected patients and their potential …
Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing
T Nguyen, S Akhavan, F Caby, L Bonyhay… - International journal of …, 2019 - Elsevier
More data on resistance of HCV genotype (GT) 3 and 4 to direct-acting antivirals (DAAs) are
still needed. Here we investigated the presence of resistance-associated substitutions …
still needed. Here we investigated the presence of resistance-associated substitutions …
Prevalence and pattern of resistance in NS5A/NS5B in hepatitis C chronic patients genotype 3 examined at a public health laboratory in the State of São Paulo, Brazil
AP de Torres Santos, VC Martins Silva… - Infection and Drug …, 2021 - Taylor & Francis
Purpose Globally, it is estimated that 71 million people are chronically infected with hepatitis
C, and 10–20% of these will develop cirrhosis and hepatocellular carcinoma. The …
C, and 10–20% of these will develop cirrhosis and hepatocellular carcinoma. The …
Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in …
Abstract Introduction Resistance-associated substitutions (RASs) in the NS5A gene of
hepatitis C virus (HCV) has been studied as one of the predictors of response to NS5A …
hepatitis C virus (HCV) has been studied as one of the predictors of response to NS5A …
Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection
I Esposito, S Marciano, L Haddad, O Galdame… - Viruses, 2018 - mdpi.com
This study aimed to assess the prevalence of natural resistance-associated substitutions
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
(RASs) to NS3, NS5A and NS5B inhibitors in 86 genotype 1 Hepatitis C Virus (HCV) …
Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1–4 in Italy
A Bertoli, MC Sorbo, M Aragri, I Lenci, E Teti, E Polilli… - Scientific reports, 2018 - nature.com
Natural resistance-associated substitutions (RASs) are reported with highly variable
prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large …
prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large …
Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
J Dietz, OV Kalinina, J Vermehren… - Journal of viral …, 2020 - Wiley Online Library
Data on the prevalence of resistance‐associated substitutions (RASs) and their implications
for treatment with direct‐acting antivirals (DAAs) are sparse in European patients with HCV …
for treatment with direct‐acting antivirals (DAAs) are sparse in European patients with HCV …